Experimental chemo combo aims to help kids with rare secondary blood cancers

NCT ID NCT05656248

Ongoing Disease control Sponsor: St. Jude Children's Research Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a chemotherapy drug called CPX-351 (Vyxeos) in 25 patients under 22 years old who have secondary myeloid neoplasms, a type of blood cancer that develops after previous cancer treatment. Participants receive one or two rounds of CPX-351, followed by a stem cell transplant. The goal is to see if the drug can safely achieve complete remission before transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CPX-351 (Vyxeos), a chemotherapy drug
What this could lead to: If it works, this could point toward a treatment that helps young patients with secondary myeloid neoplasms achieve remission before a stem cell transplant.
What could go wrong: This is a small, early-phase pilot study with only 25 participants, so results may not apply to everyone. The chemotherapy has significant side effects, including severe blood cell count drops and organ toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia juvenile myelomonocytic leukemia Myelodysplastic Syndromes myeloid neoplasm therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOID NEOPLASM

Contacts and locations

Locations

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.